Bayer Sells Cancer Drug to Gruenenthal for Up to $431 Million
By Adria Calatayud
Bayer agreed to sell rights to its cancer drug Stivarga to Gruenenthal Group for up to 375 million euros ($430.7 million), the acquirer said Monday.
The drug, due to lose patent protection in the European Union in 2029 and in the U.S. a year later, is approved to treat advanced forms of metastatic colorectal cancer, hepatocellular carcinoma and gastrointestinal stromal tumors, German drugmaker Gruenenthal said.
For Bayer, the deal comes after the German agricultural-and-pharmaceutical group completed the sale of a minority stake in its long-acting reversible contraceptives business to Apollo for around 3 billion euros earlier this month.
Gruenenthal said the acquisition marks the latest step in its strategy to acquire established drugs that serve continuing medical needs. The company said it expects the acquisition to lift its 2027 earnings before interest, taxes, depreciation and amortization by up to around 100 million euros.
The deal is expected to close by the end of 2026 or early 2027, subject to customary closing conditions, Gruenenthal said.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
September 21, 2026 08:24 ET (12:24 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States